Cargando…
Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions
Many drugs that have been proposed for treatment of COVID-19 are reported to cause cardiac adverse events, including ventricular arrhythmias. In order to properly weigh risks against potential benefits, particularly when decisions must be made quickly, mathematical modeling of both drug disposition...
Autores principales: | Varshneya, Meera, Irurzun-Arana, Itziar, Campana, Chiara, Dariolli, Rafael, Gutierrez, Amy, Pullinger, Taylor K., Sobie, Eric A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273296/ https://www.ncbi.nlm.nih.gov/pubmed/32511528 http://dx.doi.org/10.1101/2020.05.21.20109397 |
Ejemplares similares
-
Investigational Treatments for COVID‐19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions
por: Varshneya, Meera, et al.
Publicado: (2021) -
Investigational Treatments for COVID-19 May Increase Ventricular Arrhythmia Risk through Drug Interactions
por: Varshneya, Meera, et al.
Publicado: (2021) -
In vitro and In silico Models to Study SARS-CoV-2 Infection: Integrating Experimental and Computational Tools to Mimic “COVID-19 Cardiomyocyte”
por: Dariolli, Rafael, et al.
Publicado: (2021) -
Inflammation as a Risk Factor in Cardiotoxicity: An Important Consideration for Screening During Drug Development
por: Campana, Chiara, et al.
Publicado: (2021) -
Investigation of pathomechanisms of ventricular arrhythmias in cardiac laminopathies
por: Muchir, Antoine
Publicado: (2015)